Luke Timmerman, a respected biotechnology journalist known for his past work at The Seattle Times and Xconomy, today launched a new subscription-based biotech news… Read More
Amgen dealt a blow to Seattle’s biotech industry last week with the announcement that it will be closing its large research-and-development campus… Read More
—Mason Morfit, president of ValueAct Capital, has joined Microsoft’s board and will also serve on the board’s audit committee. Morfit’s appointment is part… Read More